OncLive.com· @OncLive · X·· 1 天前评分70
正文 · 机器翻译
📈 在接受第三代 EGFR TKI 后疾病进展时，izalontamab brengitecan (iza-bren) 在 III 期 PANKU-Lung01 研究中将中位 PFS 改善至 11.1 个月，而含铂化疗组为 5.7 个月。
@myESMO #ESMO26 #lcsm #medtwitter #oncology
🔗 阅读更多：https://www.onclive.com/view/iza-bren-improves-pfs-vs-platinum-chemo-in-egfr-mutated-nsclc-after-third-generation-tki
33 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgLBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：OncLive.com · x.com